112 results
8-K
EX-4.1
URGN
UroGen Pharma Ltd
18 Jun 24
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
5:07pm
price per Ordinary Share so reported, or (iv) in all other cases, the fair market value of an Ordinary Share as determined by an independent
8-K
EX-5.1
URGN
UroGen Pharma Ltd
18 Jun 24
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
5:07pm
for the opinions hereafter set forth. Insofar as the opinions expressed herein involve factual matters, we have relied exclusively, without independent
8-K
EX-1.1
URGN
UroGen Pharma Ltd
18 Jun 24
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
5:07pm
subsidiaries of any class of share capital.
(i) Independent Accountants. PricewaterhouseCoopers LLP, which has expressed its opinion with respect … of the Registration Statement, the Time of Sale Prospectus and the Prospectus, is (i) an independent registered public accounting firm as required by the Securities
424B5
URGN
UroGen Pharma Ltd
18 Jun 24
Prospectus supplement for primary offering
5:05pm
, ownership and disposition of the pre-funded warrants independent of their potential characterization as ordinary shares.
Our position with respect … of the distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all
424B5
URGN
UroGen Pharma Ltd
17 Jun 24
Prospectus supplement for primary offering
4:19pm
consequences associated with the purchase, ownership and disposition of the pre-funded warrants independent of their potential characterization as ordinary … the completion of the distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security
8-K
EX-99.1
kqh6jwdi opi0l
13 May 24
ENVISION data expected to support completion of UGN-102 NDA in Q3 2024
8:01am
8-K
EX-99.1
3bpnyds3dvr3k hwdnl
4 Mar 24
Regulation FD Disclosure
7:00am
8-K
EX-99.1
zcv9g0uy
7 Feb 24
Regulation FD Disclosure
4:15pm
S-8
EX-23.1
ahhq0 kvsk
14 Nov 23
Registration of securities for employees
4:20pm
S-8
npk157jgxjt7v5qmk8b
14 Nov 23
Registration of securities for employees
4:20pm
8-K
cyqtgjg1lg0m 8ir
11 Sep 23
Departure of Directors or Certain Officers
4:15pm